ClinicalTrials.gg
TerminatedNCT02075463Updated Aug 4, 2026Results posted

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

A Phase 2 interventional study of GSK1278863 and Placebo in Anemia and Anaemia, sponsored by GlaxoSmithKline. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
25th of 30
15 · median 76
Started
2014
with 2 others
Phase 2
10 of 30
none open now
Registered
9th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 25th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 2, and was the 9th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

The study will evaluate the ability of GSK1278863 to increase the hemoglobin (Hgb) concentration, or maintain it within the target range, and the safety and efficacy of GSK1278863 over 16 weeks of treatment, in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are chronically hyporesponsive to rhEPO. The data generated will inform dose requirements for any chronic rhEPO hyporesponsive hemodialysis-dependent subjects included in future clinical trials. The study consists of a 4-week rhEPO run-in period, a 16-week GSK1278863 treatment period and a 4-week Follow-up period.

03

Conditions studied

  • Anemia
  • Anaemia

Keywords

  • recombinant human erythropoietin
  • GSK1278863
  • hemodialysis
  • anemia
  • Hemoglobin
  • chronic rhEPO hyporesponsiveness
  • chronic kidney disease
  • erythropoiesis stimulating agents
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hemodialysis (HD) frequency: Stable HD regimen of three to four times weekly for a minimum of 12 weeks. Note: The type and frequency of dialysis must be stable during the study. Isolated ultrafiltration sessions for the purposes of fluid removal are permitted.
  • Dialysis Adequacy: Single-pool dialyzer clearance multiplied by dialyzer time divided by volume of distribution of urea (Kt/Vurea) of >=1.2 based on a historical value obtained within the prior month.
  • rhEPO hyporesponsiveness: Historical and current intravenous (IV) rhEPO and values. Average epoetin alfa dose and Hgb level for three 4-week periods for a total of 12 weeks prior to Week -4, and during the 4 week run-in period, must be within the following ranges: average epoetin alfa dose >4000 and \<=6000 units per session and Hgb >=8.0 and \<=9.5 g/dL; average epoetin alfa dose >6000 and \<=8000 units per session and Hgb >=8.0 and \<=10.0 g/dL; average epoetin alfa dose >8000 and \<=10000 units per session and Hgb >=8.0 and \<=10.5 g/dL; and average epoetin alfa dose >10000 units per session and Hgb >=8.0 and \<=11.0 g/dL.
  • Absolute difference between the Hgb value at Week -4 and Week 0 (Day 1), must be \<1.3 g/dL. Note: Subjects who do not meet the criteria after being rescreened twice, should not be entered into the GSK1278863 treatment period and should be withdrawn from the study.
  • Age: >=18 years of age.
  • Q-T Interval Corrected for Heart Rate (): Bazett's Correction of QT Interval (QTcB) \<470 msec or QTcB \<480 milliseconds (msec) in subjects with bundle branch block. There is no corrected QT interval (QTc) inclusion criterion for a subject with a predominantly paced rhythm.
  • Gender: Female and male subjects. Females: If of , must agree to use one of the approved methods from Screening until completion of the Follow-up Visit OR, of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy or oophorectomy; or defined as 12 months of spontaneous amenorrea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 milliinternational units (MIU)/milliliter (mL) (23.0-116.3 international units (IU)/liter (L)) and estradiol \<=10 picograms (pg)/mL (\<=37 picomole (pmol)/L) is confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.

Exclusion criteria

Exclusion Criteria:

  • Dialysis modality: Planned change in dialysis modality within the study time period.
  • rhEPO: Use of methoxy polyethylene glycol epoetin beta or darbepoetin within the prior 8 weeks prior to Week -4.
  • Renal transplant: Scheduled renal transplant.
  • Transferrin saturation (TSAT): \<20% on the most recent sample taken over the last 12 weeks.
  • Ferritin: \<100 nanograms (ng)/mL (\<100 micrograms/L) on the most recent sample taken over the last 12 weeks.
  • Vitamin B12: At or below the lower limit of the reference range (may rescreen in a minimum of 8 weeks).
  • Folate: \<2.0 ng/mL (\<4.5 nanomoles (nmol)/L) (may rescreen in a minimum of 4 weeks).
  • Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Week -4.
  • Stroke or (TIAs): Within the 8 weeks prior to Week -4.
  • Heart failure: Class III/IV heart failure, as defined by the (NYHA) functional classification system diagnosed prior to Week -4.
  • Hypertension: Defined using pre-dialysis vitals (Week -4) of diastolic blood pressure >100 millimeters of mercury (mmHg) or systolic blood pressure >170 mmHg.
  • Thrombotic disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention) within the 8 weeks prior to Week -4, except vascular access thrombosis.
  • Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Week -4.
  • Hematological disease: Any hematological disease including those affecting , white or red blood cells (e.g., antibody-mediated pure red cell aplasia, sickle cell anemia, myelodysplastic syndromes, hematological , myeloma, hemolytic anemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia other than renal disease diagnosed prior to Week -4.
  • Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [ (ALT) or aspartate transaminase (AST) > 2.0 x (ULN) or total > 1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study. NOTE: Those with or are eligible provided these exclusions are not met.
  • Major surgery: (excluding vascular access surgery) within the 8 weeks prior to Week -4, or planned during the study.
  • Transfusion: Blood transfusion within the 8 weeks prior to Week -4, or an anticipated need for blood transfusion during the study.
  • Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease or GI bleeding within the 8 weeks prior to Week -4.
  • Ophthalmology disease: History of proliferative retinopathy requiring treatment within the prior 12 months or macular edema requiring treatment.
  • Acute infection: Clinical evidence of acute infection, evidence of underlying infection or history of infection requiring IV antibiotic therapy within the 8 weeks prior to Week -4, and also through to Day 1. Note: IV antibiotics as prophylaxis are allowed.
  • Malignancy: Subjects with a history of malignancy within the prior 5 years, who are receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to Week -4.
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to in the product.
  • Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Week -4 until the Follow-up Visit.
  • Prior investigational product exposure: The subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days to Week -4.
  • : Life expectancy is considered by the investigator to be less than 6 months.
  • Other conditions: Any other conditions, clinical or laboratory abnormality, or examination finding that the Investigator considers would put the subject at unacceptable risk, or an unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol.
  • Pregnancy and lactation: Pregnant females as determined by positive serum human chorionic gonadotrophin (hCG) test or women who are lactating at Week -4 or during the trial.
  • Laboratory eligibility criteria will be assessed according to the central laboratory result for the screening samples
  • Subjects who fail screening may be rescreened as soon as the investigator feels they may have subsequently become eligible. However, an individual subject may not be rescreened more than twice. There is no predetermined amount of time required to wait to rescreen a previously ineligible subject. Exceptions are those failing on or folate who may rescreen in 4 weeks and those failing for Vitamin B12 where rescreening may occur in 8 weeks.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    GSK1278863 Arm

    Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid

    Drug: GSK1278863 · Drug: Placebo

Interventions

  • Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863

  • DrugPlacebo

    Matching placebo tablet for GSK1278863

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16

    Percentage of participants with increased Hgb \>=1 g/dL (if baseline Hgb is \<9.5 g/dL), or \>=0.5 g/dL (if baseline Hgb is 9.5-\<10 g/dL), or within the target range and not dropped by \>0.5 g/dL (if baseline Hgb is \>= 10 g/dL) at Week 16 are presented. Participants who were available at the indicated time point were analyzed

    Time frame: Week 16

Secondary outcomes

  1. Change From Baseline in Hgb Levels at Week 16

    Hgb values measured at Week 16 are presented. Change from baseline was calculated as Week 16 minus baseline value . Participants who were available at the indicated time point were analyzed.

    Time frame: Week 16

  2. Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time Point

    The percentage of time in Hgb levels were in target range (10.0 to 11.5 g/dL) between Weeks 12 and 16 for a participant was calculated by adding the total number of days that Hgb is within target range while on treatment during Weeks 12 to 16 and dividing by the total number of days the participant remained on treatment during Weeks 12 to 16 (using Rosendaal linear interpolation method). Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated. Participants who were available at the indicated time point were analyzed.

    Time frame: Week 12 to Week 16

  3. Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16

    Number of participants achieving at least 1 g/dL increase in Hgb from baseline at Week 16 were presented. Participants who were available at the indicated time point were analyzed.

    Time frame: Baseline and Week 16

  4. Number of Participants With Hgb in the Target Range at Week 16

    The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 16 were analyzed. Participants who were available at the indicated time point were analyzed.

    Time frame: Week 16

  5. Number of Participants Reaching Pre-defined Hgb Stopping Criteria

    The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL from baseline to Week 16 were presented. Participants who were available at the indicated time point were analyzed.

    Time frame: Up to Week 16

  6. Percent Change From Baseline in Hepcidin at Week 16

    Hepcidin is a regulator of iron metabolism. Baseline value for hepcidin is the pre-dose value on Day 1. Percent change was calculated as 100 multiplied by \[exponential (log Week 16 value - log Baseline value) minus 1\]. Participants who were available at the indicated time point were analyzed.

    Time frame: Baseline (Day 1) and Week 16

  7. Change From Baseline in Ferritin at Week 16

    Baseline value for ferritin is the last pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.

    Time frame: Baseline (Day 1) and Week 16

  8. Change From Baseline in Transferrin at Week 16

    Baseline value for transferrin is the last pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.

    Time frame: Baseline (Day 1) and Week 16

  9. Percent Change From Baseline in Transferrin Saturation at Week 16

    Transferrin saturation is measured in percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change is 100 times \[exponential (log Week 16 value minus log Baseline value) -1\]. Participants who were available at the indicated time point were analyzed.

    Time frame: Baseline (Day 1) and Week 16

  10. Change From Baseline in Total Iron at Week 16

    Baseline value for total iron is the last pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

    Time frame: Baseline (Day 1) and Week 16

  11. Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 16

    Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the last pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

    Time frame: Baseline (Day 1) and Week 16

  12. Reticulocyte Hgb Content (CHr) at Week 16

    Data has been presented for only those participants who were available at indicated timepoints

    Time frame: Week 16

  13. Mean Corpuscular Volume (MCV) at Week 16

    Data has been presented for only those participants who were available at indicated time points.

    Time frame: Week 16

  14. Mean Corpuscular Hemoglobin (MCH) at Week 16

    Data has been presented for only those participants who were available at indicated time points.

    Time frame: Week 16

  15. Change From Baseline in Hematocrit at Week 16

    Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

    Time frame: Baseline (Day 1) and Week 16

  16. Change From Baseline in Red Blood Cell (RBC) at Week 16

    Baseline value for RBC (or erythrocytes) is the last pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points

    Time frame: Baseline (Day 1) and Week 16

  17. Change From Baseline in Reticulocyte Number at Week 16

    Baseline value for reticulocyte number is the pre-dose value on Day 1. Change from Baseline in reticulocyte number was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

    Time frame: Baseline (Day 1) and Week 16

  18. Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

    Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF in the subjects was reported. Baseline value for VEGF is the last pre-dose value on Day 1. Percent change was calculated as 100 multiplied by exponential (log observed maximum value minus log Baseline value) minus 1. Participants who were available at the indicated time point were analyzed.

    Time frame: Baseline (Day 1) to Week 16

  19. Maximum Observed Change From Baseline in Erythropoietin (EPO)

    Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was reported. Baseline value for EPO is the last pre-dose value on Day 1. Change from baseline is calculated as the maximum observed value minus the baseline value. Participants who were available at the indicated time point were analyzed.

    Time frame: Baseline (Day 1) to Week 16

  20. Final Dose of GSK1278863

    For the first 4 weeks, subjects received 12mg QD of GSK1278863 with dose decrease permitted at Week 2. After 4 weeks of treatment with GSK1278863, need for dose adjustment was evaluated at visits 4, 8 and 12, to maintain hemoglobin within the target range. Target range was defined as: Hgb Criteria of 10.0 to 11.5 g/dL. Data has been presented for only those participants who were available at indicated time points.

    Time frame: Up to 16 Weeks

  21. Plasma Concentrations of GSK1278863 and Its Metabolites at the Indicated Time Points

    Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD\]), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W12 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.

    Time frame: Day 1, Week 4 and Week 12

07

Results

Posted Jun 21, 2017
Limitations and caveats
Due to the study terminating early, resulting in a sparse amount of data, selected parameters were not summarized.

Participant flow

Eligible hemodialysis-dependent participants (par.) with anemia associated with chronic kidney disease and chronically hyporesponsive to recombinant human erythropoietin (rhEPO) (for 12 weeks) were switched from a stable dose of rhEPO

Participant flow — Overall Study
MilestoneGSK1278863 12 mg QD
Started15
Completed7
Not completed8
Withdrew: Adverse event3
Withdrew: Par. reached stopping criteria4
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16

Percentage of participants with increased Hgb \>=1 g/dL (if baseline Hgb is \<9.5 g/dL), or \>=0.5 g/dL (if baseline Hgb is 9.5-\<10 g/dL), or within the target range and not dropped by \>0.5 g/dL (if baseline Hgb is \>= 10 g/dL) at Week 16 are presented. Participants who were available at the indicated time point were analyzed

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16
Percentage of participantsGSK1278863 12 mg QD
Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 1628.6 (8.2 to 64.1)
SecondaryChange From Baseline in Hgb Levels at Week 16

Hgb values measured at Week 16 are presented. Change from baseline was calculated as Week 16 minus baseline value . Participants who were available at the indicated time point were analyzed.

Time frame:
Week 16
Reported as:
Mean · g/dL
Change From Baseline in Hgb Levels at Week 16
g/dLGSK1278863 12 mg QD
Change From Baseline in Hgb Levels at Week 160.10 ± 1.319
SecondaryPercentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time Point

The percentage of time in Hgb levels were in target range (10.0 to 11.5 g/dL) between Weeks 12 and 16 for a participant was calculated by adding the total number of days that Hgb is within target range while on treatment during Weeks 12 to 16 and dividing by the total number of days the participant remained on treatment during Weeks 12 to 16 (using Rosendaal linear interpolation method). Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated. Participants who were available at the indicated time point were analyzed.

Time frame:
Week 12 to Week 16
Reported as:
Mean · Percentage of days
Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time Point
Percentage of daysGSK1278863 12 mg QD
Within Target Range48.28 ± 46.102
Above target range0.92 ± 2.605
Below target range50.80 ± 47.176
SecondaryNumber of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16

Number of participants achieving at least 1 g/dL increase in Hgb from baseline at Week 16 were presented. Participants who were available at the indicated time point were analyzed.

Time frame:
Baseline and Week 16
Reported as:
Number · Participants
Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16
ParticipantsGSK1278863 12 mg QD
Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 162
SecondaryNumber of Participants With Hgb in the Target Range at Week 16

The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 16 were analyzed. Participants who were available at the indicated time point were analyzed.

Time frame:
Week 16
Reported as:
Number · Participants
Number of Participants With Hgb in the Target Range at Week 16
ParticipantsGSK1278863 12 mg QD
Number of Participants With Hgb in the Target Range at Week 162
SecondaryNumber of Participants Reaching Pre-defined Hgb Stopping Criteria

The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL from baseline to Week 16 were presented. Participants who were available at the indicated time point were analyzed.

Time frame:
Up to Week 16
Reported as:
Number · Participants
Number of Participants Reaching Pre-defined Hgb Stopping Criteria
ParticipantsGSK1278863 12 mg QD
Number of Participants Reaching Pre-defined Hgb Stopping Criteria3
SecondaryPercent Change From Baseline in Hepcidin at Week 16

Hepcidin is a regulator of iron metabolism. Baseline value for hepcidin is the pre-dose value on Day 1. Percent change was calculated as 100 multiplied by \[exponential (log Week 16 value - log Baseline value) minus 1\]. Participants who were available at the indicated time point were analyzed.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Geometric mean · Percent change in hepcidin
Percent Change From Baseline in Hepcidin at Week 16
Percent change in hepcidinGSK1278863 12 mg QD
Percent Change From Baseline in Hepcidin at Week 1616.49 (-12.14 to 54.43)
SecondaryChange From Baseline in Ferritin at Week 16

Baseline value for ferritin is the last pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Micrograms/Liter
Change From Baseline in Ferritin at Week 16
Micrograms/LiterGSK1278863 12 mg QD
Change From Baseline in Ferritin at Week 16-72.1 ± 134.81
SecondaryChange From Baseline in Transferrin at Week 16

Baseline value for transferrin is the last pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Percent change
Change From Baseline in Transferrin at Week 16
Percent changeGSK1278863 12 mg QD
Change From Baseline in Transferrin at Week 160.080 ± 0.2332
SecondaryPercent Change From Baseline in Transferrin Saturation at Week 16

Transferrin saturation is measured in percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change is 100 times \[exponential (log Week 16 value minus log Baseline value) -1\]. Participants who were available at the indicated time point were analyzed.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Geometric mean · Percent change in transferrin
Percent Change From Baseline in Transferrin Saturation at Week 16
Percent change in transferrinGSK1278863 12 mg QD
Percent Change From Baseline in Transferrin Saturation at Week 1618.5 (-21.4 to 78.8)
SecondaryChange From Baseline in Total Iron at Week 16

Baseline value for total iron is the last pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · Micromoles (µmol)/L
Change From Baseline in Total Iron at Week 16
Micromoles (µmol)/LGSK1278863 12 mg QD
Participant 14
Participant 221
Participant 3-3
Participant 43
Participant 52
Participant 65
Participant 7-5
SecondaryChange From Baseline in Total Iron Binding Capacity (TIBC) at Week 16

Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the last pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · µmol/ L
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 16
µmol/ LGSK1278863 12 mg QD
Participant 114
Participant 212
Participant 3-6
Participant 4-1
Participant 56
Participant 6-4
Participant 78
SecondaryReticulocyte Hgb Content (CHr) at Week 16

Data has been presented for only those participants who were available at indicated timepoints

Time frame:
Week 16
Reported as:
Number · Picogram (pg)
Reticulocyte Hgb Content (CHr) at Week 16
Picogram (pg)GSK1278863 12 mg QD
Participant 138.80
Participant 231.50
Participant 332.80
Participant 430.20
Participant 531.70
Participant 630.10
Participant 734.30
SecondaryMean Corpuscular Volume (MCV) at Week 16

Data has been presented for only those participants who were available at indicated time points.

Time frame:
Week 16
Reported as:
Number · Femtoliter (fL)
Mean Corpuscular Volume (MCV) at Week 16
Femtoliter (fL)GSK1278863 12 mg QD
Participant 1124.00
Participant 299.00
Participant 397.00
Participant 4101.00
Participant 594.00
Participant 697.00
Participant 7106.00
SecondaryMean Corpuscular Hemoglobin (MCH) at Week 16

Data has been presented for only those participants who were available at indicated time points.

Time frame:
Week 16
Reported as:
Number · pg
Mean Corpuscular Hemoglobin (MCH) at Week 16
pgGSK1278863 12 mg QD
Participant 139.80
Participant 231.30
Participant 331.70
Participant 431.60
Participant 530.90
Participant 630.70
Participant 735.70
SecondaryChange From Baseline in Hematocrit at Week 16

Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · Fraction of 1
Change From Baseline in Hematocrit at Week 16
Fraction of 1GSK1278863 12 mg QD
Participant 1-0.025
Participant 20.067
Participant 3-0.015
Participant 40.043
Participant 5-0.016
Participant 60.004
Participant 7-0.089
SecondaryChange From Baseline in Red Blood Cell (RBC) at Week 16

Baseline value for RBC (or erythrocytes) is the last pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · 10^12/L
Change From Baseline in Red Blood Cell (RBC) at Week 16
10^12/LGSK1278863 12 mg QD
Participant 1-0.3
Participant 20.7
Participant 3-0.1
Participant 40.3
Participant 5-0.1
Participant 60.2
Participant 7-0.7
SecondaryChange From Baseline in Reticulocyte Number at Week 16

Baseline value for reticulocyte number is the pre-dose value on Day 1. Change from Baseline in reticulocyte number was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · 10^12/L
Change From Baseline in Reticulocyte Number at Week 16
10^12/LGSK1278863 12 mg QD
Participant 10.0003
Participant 20.0043
Participant 3-0.0174
Participant 4-0.0139
Participant 5-0.0201
Participant 6-0.0458
Participant 7-0.0006
SecondaryMaximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF in the subjects was reported. Baseline value for VEGF is the last pre-dose value on Day 1. Percent change was calculated as 100 multiplied by exponential (log observed maximum value minus log Baseline value) minus 1. Participants who were available at the indicated time point were analyzed.

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Geometric mean · Percent change
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Percent changeGSK1278863 12 mg QD
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)58.72 (35.56 to 85.84)
SecondaryMaximum Observed Change From Baseline in Erythropoietin (EPO)

Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was reported. Baseline value for EPO is the last pre-dose value on Day 1. Change from baseline is calculated as the maximum observed value minus the baseline value. Participants who were available at the indicated time point were analyzed.

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Mean · international units(IU)/Liter (L)
Maximum Observed Change From Baseline in Erythropoietin (EPO)
international units(IU)/Liter (L)GSK1278863 12 mg QD
Maximum Observed Change From Baseline in Erythropoietin (EPO)253.07 ± 526.670
SecondaryFinal Dose of GSK1278863

For the first 4 weeks, subjects received 12mg QD of GSK1278863 with dose decrease permitted at Week 2. After 4 weeks of treatment with GSK1278863, need for dose adjustment was evaluated at visits 4, 8 and 12, to maintain hemoglobin within the target range. Target range was defined as: Hgb Criteria of 10.0 to 11.5 g/dL. Data has been presented for only those participants who were available at indicated time points.

Time frame:
Up to 16 Weeks
Reported as:
Number · mg
Final Dose of GSK1278863
mgGSK1278863 12 mg QD
Participant 125
Participant 212
Participant 325
Participant 48
Participant 512
Participant 615
Participant 710
Participant 812
Participant 90
Participant 1012
Participant 1112
Participant 1215
Participant 1315
Participant 1415
Participant 1525
SecondaryPlasma Concentrations of GSK1278863 and Its Metabolites at the Indicated Time Points

Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD\]), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W12 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.

Time frame:
Day 1, Week 4 and Week 12
Reported as:
Mean · ng/mL
Plasma Concentrations of GSK1278863 and Its Metabolites at the Indicated Time Points
ng/mLGSK1278863 12 mg QD
GSK1278863, D1, PrD, n=150 ± 0
GSK1278863, W4, 6-12 hr PoD, n=1364.8 ± 166.48
GSK1278863, W4, 7-13 hr PoD, n=1388.6 ± 213.55
GSK1278863, W4, 8-14 hr PoD, n=1379 ± 204.25
GSK1278863, W4, 9-15 hr PoD, n=1367.4 ± 186.84
GSK1278863, W12, PrD, n=818 ± 34.15
GSK1278863, W12, 0.5-1 hr PoD, n=8125 ± 186.65
GSK1278863, W12, 2 hr PoD, n=8103.7 ± 140.78
GSK1278863, W12, 3 hr PoD, n=840.6 ± 32.53
GSK2391220, D1, PrD, n=150 ± 0
GSK2391220, W4, 6-12 hr PoD, n=1341.3 ± 19.16
GSK2391220, W4, 7-13 hr PoD, n=1322.6 ± 10
GSK2391220, W4, 8-14 hr PoD, n=1316.7 ± 8.03
GSK2391220, W4, 9-15 hr PoD, n=1312.9 ± 6.95
GSK2391220, W12, PrD, n=825.9 ± 22.79
GSK2391220, W12, 0.5-1 hr PoD, n=824.9 ± 21.63
GSK2391220, W12, 2 hr PoD, n=823.7 ± 19.94
GSK2391220, W12, 3 hr PoD, n=818 ± 13.43
GSK2487818, D1, PrD, n=150 ± 0
GSK2487818, W4, 6-12 hr PoD, n=1315.8 ± 11.02
GSK2487818, W4, 7-13 hr PoD, n=139.3 ± 6.1
GSK2487818, W4, 8-14 hr PoD, n=137.2 ± 4.96
GSK2487818, W4, 9-15 hr PoD, n=135.8 ± 4.97
GSK2487818, W12, PrD, n=86.5 ± 9.01
GSK2487818, W12, 0.5-1 hr PoD, n=810.6 ± 10.87
GSK2487818, W12, 2 hr PoD, n=815.6 ± 19.22
GSK2487818, W12, 3 hr PoD, n=811.6 ± 11.17
GSK2506102, D1, PrD, n=150 ± 0
GSK2506102, W4, 6-12 hr PoD, n=1313.6 ± 6.55
GSK2506102, W4, 7-13 hr PoD, n=137.5 ± 3.34
GSK2506102, W4, 8-14 hr PoD, n=135.6 ± 2.6
GSK2506102, W4, 9-15 hr PoD, n=134.3 ± 2.24
GSK2506102, W12, PrD, n=810 ± 7.54
GSK2506102, W12, 0.5-1 hr PoD, n=87.9 ± 6.53
GSK2506102, W12, 2 hr PoD, n=86.3 ± 4.14
GSK2506102, W12, 3 hr PoD, n=84.9 ± 3.2
GSK2531398, D1, PrD, n=150 ± 0
GSK2531398, W4, 6-12 hr PoD, n=1316.6 ± 9.12
GSK2531398, W4, 7-13 hr PoD, n=139.4 ± 4.98
GSK2531398, W4, 8-14 hr PoD, n=137.1 ± 4.04
GSK2531398, W4, 9-15 hr PoD, n=135.6 ± 3.5
GSK2531398, W12, PrD, n=88.2 ± 7.78
GSK2531398, W12, 0.5-1 hr PoD, n=88.5 ± 7.57
GSK2531398, W12, 2 hr PoD, n=89.3 ± 8.71
GSK2531398, W12, 3 hr PoD, n=87.3 ± 5.75
GSK2531401, D1, PrD, n=150 ± 0
GSK2531401, W4, 6-12 hr PoD, n=1328.4 ± 11.94
GSK2531401, W4, 7-13 hr PoD, n=1315.6 ± 5.64
GSK2531401, W4, 8-14 hr PoD, n=1311.6 ± 4.43
GSK2531401, W4, 9-15 hr PoD, n=138.7 ± 3.22
GSK2531401, W12, PrD, n=827.8 ± 22.34
GSK2531401, W12, 0.5-1 hr PoD, n=821 ± 19.46
GSK2531401, W12, 2 hr PoD, n=814.6 ± 11.05
GSK2531401, W12, 3 hr PoD, n=811.2 ± 8.83
GSK2531403, D1, PrD, n=150 ± 0
GSK2531403, W4, 6-12 hr PoD, n=1351.8 ± 22.75
GSK2531403, W4, 7-13 hr PoD, n=1328.2 ± 11.85
GSK2531403, W4, 8-14 hr PoD, n=1320.6 ± 9.34
GSK2531403, W4, 9-15 hr PoD, n=1315.8 ± 8.07
GSK2531403, W12, PrD, n=835.8 ± 28.09
GSK2531403, W12, 0.5-1 hr PoD, n=830.6 ± 25.2
GSK2531403, W12, 2 hr PoD, n=825.7 ± 18.15
GSK2531403, W12, 3 hr PoD, n=819.6 ± 13.14

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study treatment and until the follow up (up to 20 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1278863 12 mg QD—9/15 (60%)11/15 (73.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventGSK1278863 12 mg QD
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/15
ANGINA UNSTABLECardiac disorders1/15
CARDIAC ARRESTCardiac disorders1/15
VENTRICULAR TACHYCARDIACardiac disorders1/15
GASTROENTERITIS VIRALInfections and infestations1/15
PNEUMONIAInfections and infestations1/15
PNEUMONIA MYCOPLASMALInfections and infestations1/15
GASTROINTESTINAL STOMA COMPLICATIONInjury, poisoning and procedural complications1/15
PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications1/15
HAEMATOMAVascular disorders1/15
Most frequent other events
Showing 10 of 23
Most frequent other events
EventGSK1278863 12 mg QD
NAUSEAGastrointestinal disorders3/15
URINARY TRACT INFECTIONInfections and infestations2/15
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders2/15
GASTROENTERITIS VIRALInfections and infestations1/15
INFLUENZAInfections and infestations1/15
PNEUMONIAInfections and infestations1/15
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/15
VOMITINGGastrointestinal disorders1/15
BLOOD CALCIUM DECREASEDInvestigations1/15
BLOOD PRESSURE INCREASEDInvestigations1/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1278863 12 mg QD
Mean59.1 ± 12.76
Sex: Female, Male
Sex: Female, Male(Participants)GSK1278863 12 mg QD
Female7
Male8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1278863 12 mg QD
BLACK OR AFRICAN AMERICAN2
WHITE13
08

Study locations

10 sites
  • GSK Investigational Site
    Azusa, California 91702, United States
  • GSK Investigational Site
    Glendale, California 91204, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Simi Valley, California 93065, United States
  • GSK Investigational Site
    Hollywood, Florida 33024, United States
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
  • GSK Investigational Site
    Amherst, New York 14226, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18017, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37923, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
09

References and documents

Publications

  • Cizman B, Sykes AP, Paul G, Zeig S, Cobitz AR. An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects. Kidney Int Rep. 2018 Mar 3;3(4):841-850. doi: 10.1016/j.ekir.2018.02.009. eCollection 2018 Jul. PubMed 29989040 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in Mar 2016, 21 months.

Results were first posted in Jun 2017, 1 year 3 months after primary completion. A results delay was requested in Aug 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2014
First posted
Mar 3, 2014
StartActual
Jun 11, 2014
Primary completionActual
Mar 16, 2016
CompletionActual
Mar 16, 2016
Results delay requested
Aug 4, 2016
Results first posted
Jun 21, 2017
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02075463
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Jun 11, 2014
Primary completion
Mar 16, 2016
Completion
Mar 16, 2016
Results posted
Jun 21, 2017
Last update
Aug 4, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion